생물제제 안전성 시험 시장 : 제공 형태, 시험 유형, 제형, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Biologics Safety Testing Market is projected to grow by USD 10.09 billion at a CAGR of 11.03% by 2032.

Biologics Safety Testing Market Introduction

Biologics safety testing is a mission-critical quality and regulatory function for monoclonal antibodies, recombinant proteins, vaccines, biosimilars, cell therapies, gene therapies, and other complex biopharmaceutical products. The field covers sterility testing, endotoxin testing, mycoplasma testing, viral safety testing, adventitious agent detection, cell line characterization, residual host cell protein and DNA analysis, bioburden testing, and product-specific potency and impurity assessments.

Demand is being reinforced by the global expansion of biologics pipelines, higher biosimilar development activity, and the scale-up of advanced therapies that require risk-based, product-specific biosafety strategies. Regulatory expectations from FDA, EMA, ICH, USP, Ph. Eur., and WHO continue to emphasize validated methods, GMP-aligned documentation, contamination control, data integrity, and lifecycle management, making biologics safety testing a core enabler of product approval, batch release, and patient protection.

Transformative Shifts in the Biologics Safety Testing Landscape

The biologics safety testing landscape is shifting from end-point quality control toward integrated contamination control across development, manufacturing, and release. Rapid microbiological methods, molecular assays, next-generation sequencing, automated sample handling, and electronic laboratory workflows are increasingly used alongside compendial tests to improve speed, sensitivity, and investigation quality while maintaining regulatory comparability.

Cell and gene therapies are accelerating this transformation because they often involve short shelf lives, small batch sizes, autologous workflows, viral vectors, complex raw materials, and limited opportunities for extended release testing. At the same time, global outsourcing to specialized CROs, CDMOs, and contract testing laboratories is expanding as sponsors seek validated platforms, biosafety expertise, surge capacity, and integrated support for viral clearance, adventitious virus testing, mycoplasma testing, and GMP release testing.

Cumulative Impact of Artificial Intelligence on Biologics Safety Testing

Artificial intelligence is beginning to influence biologics safety testing through predictive contamination monitoring, anomaly detection in environmental monitoring data, automated review of batch records, and smarter assay development. In high-throughput laboratories, AI-enabled analytics can support trend analysis across sterility, bioburden, endotoxin, viral safety, and mycoplasma datasets, helping quality teams identify deviations earlier and prioritize investigations.

The cumulative impact is operational rather than speculative: AI can reduce manual review burden, improve data integrity checks, support method optimization, and strengthen risk-based quality management when validated within GMP expectations. Adoption remains governed by requirements for explainability, audit trails, cybersecurity, human oversight, and computer system validation, particularly where AI outputs inform release decisions, deviation management, or regulatory submissions.

Key Regional Insights Across Global Biologics Safety Testing

North America remains a leading biologics safety testing hub due to the concentration of biopharmaceutical innovators, FDA-regulated manufacturing, advanced therapy developers, academic translational centers, and specialized contract testing laboratories. The region benefits from mature GMP inspection systems, extensive biologics clinical development, and strong adoption of validated rapid methods for sterility, endotoxin, mycoplasma, and viral safety testing. Europe is similarly mature, supported by EMA oversight, strong national regulatory agencies, the European Pharmacopoeia, and extensive biologics and biosimilar manufacturing across Germany, France, Italy, Spain, and the United Kingdom, with regulatory emphasis on comparability, contamination control strategy, and pharmacopoeial compliance.

Asia-Pacific is one of the most dynamic regions, driven by biologics capacity expansion in China, India, Japan, South Korea, Australia, and ASEAN markets, alongside government support for domestic vaccine production, biosimilars, and advanced therapy development. Latin America is gaining relevance through vaccine production, biosimilar commercialization, public health procurement, and regulatory convergence led by Brazil and Mexico. The Middle East is investing in biomanufacturing localization, healthcare security, and technology transfer programs that increase demand for GMP-aligned safety testing. Africa is building vaccine and biologics quality infrastructure through regional manufacturing initiatives, regulatory strengthening, and international partnerships focused on local production resilience and biologics quality assurance.

Key Group Insights for Biologics Safety Testing Demand

ASEAN is emerging as a manufacturing and clinical development corridor, with Singapore and regional hubs supporting bioprocessing, analytical services, regulatory reliance pathways, and supply chain resilience for biologics and vaccines. The GCC is prioritizing healthcare diversification, life sciences investment, and local pharmaceutical capability, creating demand for GMP testing partnerships, technology transfer, laboratory qualification, and regulatory readiness for biologics, biosimilars, and vaccines.

The European Union benefits from harmonized rules, established pharmacopoeial standards, centralized regulatory procedures, and strong biosimilar experience, making it a reference market for compliance-led safety testing. BRICS countries are central to future development activity because China, India, and Brazil combine large patient populations with expanding biologics manufacturing, while Russia and South Africa maintain policy-driven interest in domestic biologics and vaccine capabilities. G7 markets remain technology leaders in advanced testing platforms, digital quality systems, cell and gene therapy oversight, and high-complexity analytical validation. NATO-aligned countries emphasize secure supply chains, pandemic preparedness, regulatory interoperability, and resilient biopharmaceutical quality systems, reinforcing the role of biologics safety testing in national health security.

Key Country Insights in Biologics Safety Testing

The United States leads in advanced biologics, cell and gene therapy development, FDA-regulated manufacturing, and outsourced biosafety testing capacity, with strong demand for viral safety, sterility, endotoxin, mycoplasma, and release testing services. Canada supports clinical research, vaccine capabilities, regulated biologics manufacturing, and quality systems aligned with international GMP expectations. Mexico is strengthening its role in Latin American pharmaceutical manufacturing and regulatory modernization, while Brazil holds strong regional influence in vaccines, biosimilars, public health procurement, and biologics quality infrastructure.

In Europe, the United Kingdom, Germany, France, Italy, and Spain offer strong regulatory, manufacturing, and clinical trial ecosystems, with Germany and France anchored by advanced bioprocessing capabilities, Italy and Spain supported by established pharmaceutical production networks, and the United Kingdom reinforced by translational research and advanced therapy development. Russia maintains domestic biologics and vaccine capabilities shaped by local policy priorities and supply security objectives. China and India are expanding rapidly through biosimilars, recombinant products, vaccines, CDMO services, and investments in analytical testing capacity. Japan, Australia, and South Korea contribute high-quality regulatory environments, advanced biomanufacturing, strong clinical research systems, and broad adoption of validated analytical technologies for biologics safety testing.

Actionable Recommendations for Biologics Safety Testing Leaders

Vendors should align biologics safety testing strategy with the full product lifecycle, beginning with raw material qualification, cell substrate characterization, viral risk assessment, contamination control planning, and assay suitability evaluation. Sponsors should select partners with proven GMP systems, validated assays, global regulatory experience, robust data integrity controls, and capacity for urgent release testing, especially for advanced therapies, personalized medicines, and short-shelf-life products.

Organizations should also invest in digital quality systems, laboratory information management, method lifecycle management, and risk-based validation of rapid microbiological and molecular methods. Building redundancy across qualified laboratories, harmonizing global specifications, maintaining clear comparability documentation, and engaging regulators early can reduce approval delays, strengthen supply continuity, and improve confidence in biologics safety data. Leaders should prioritize cross-functional governance among quality, regulatory, manufacturing, and analytical development teams to ensure biosafety decisions are scientifically justified and inspection-ready.

Research Methodology for Biologics Safety Testing Analysis

This executive summary is developed from a structured review of verified regulatory frameworks, pharmacopoeial requirements, public agency guidance, industry standards, and observed biopharmaceutical manufacturing trends. The analysis considers FDA, EMA, ICH, USP, Ph. Eur., WHO, PIC/S, and OECD-aligned principles where relevant to sterility, endotoxin, mycoplasma, viral safety, adventitious agent testing, cell substrate characterization, and GMP quality systems.

The methodology combines secondary research, market triangulation, segment mapping, and qualitative assessment of technology adoption across biologics, biosimilars, vaccines, and cell and gene therapies. Insights are evaluated by region, country, and strategic group to identify demand drivers, compliance pressures, outsourcing patterns, regulatory expectations, and operational priorities for biologics safety testing providers and sponsors, while avoiding unsupported market sizing, market share, or forecasting claims.

Conclusion: Strategic Outlook for Biologics Safety Testing

Biologics safety testing is becoming more strategic as products grow more complex, manufacturing networks globalize, and regulators intensify expectations for contamination control, validated methods, and data integrity. The market is supported by durable demand for viral safety testing, sterility testing, endotoxin testing, mycoplasma testing, cell line characterization, residual impurity analysis, and advanced molecular assays across commercial biologics and next-generation therapies.

Organizations that combine scientific rigor, validated technology, regulatory intelligence, and scalable laboratory operations will be best positioned to support faster development, reliable batch release, and sustained patient safety. The strongest competitive advantage will come from integrating compliance, speed, digital traceability, and predictive quality into a unified biosafety testing model that meets evolving global regulatory expectations.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Biologics Safety Testing Market, by Offering

• 7.1. Instruments
  • 7.1.1. Endotoxin Readers
  • 7.1.2. PCR Systems
  • 7.1.3. Incubators
• 7.2. Reagents & Kits
• 7.3. Services
  • 7.3.1. Implementation
  • 7.3.2. Maintenance & Support
• 7.4. Solutions
  • 7.4.1. LIMS/QMS Integrations
  • 7.4.2. Assay Analysis
  • 7.4.3. Trend Monitoring

8. Biologics Safety Testing Market, by Test Type

• 8.1. Adventitious Agent Detection
• 8.2. Bioburden Testing
• 8.3. Cell Line Authentication & Characterization
• 8.4. Endotoxin Testing
• 8.5. Mycoplasma Testing
• 8.6. Residual Host Cell Protein (HCP) Testing
• 8.7. Sterility Testing

9. Biologics Safety Testing Market, by Form

• 9.1. Kit Format
• 9.2. Single-vial Reagent Format

10. Biologics Safety Testing Market, by Application

• 10.1. Gene Therapy
• 10.2. Monoclonal Antibody Production
• 10.3. Recombinant Protein Therapeutics
• 10.4. Stem Cell Research
• 10.5. Tissue Engineering
• 10.6. Vaccine Development

11. Biologics Safety Testing Market, by End User

• 11.1. Academic & Research Institutes
• 11.2. Contract Research Organizations (CROs)
• 11.3. Pharmaceutical & Biotechnology Companies

12. Biologics Safety Testing Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Biologics Safety Testing Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Biologics Safety Testing Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Agilent Technologies, Inc.
• 16.2. Associates of Cape Cod, Inc.
• 16.3. Becton, Dickinson and Company
• 16.4. Bio-Rad Laboratories, Inc.
• 16.5. bioMerieux SA
• 16.6. Bionique Testing Laboratories
• 16.7. Catalent Inc.
• 16.8. Charles River Laboratories International, Inc.
• 16.9. Clean Biologics SAS
• 16.10. Danaher Corporation
• 16.11. Eurofins Scientific SE
• 16.12. FUJIFILM Corporation
• 16.13. GenScript Biotech Corporation
• 16.14. Intertek Group plc
• 16.15. Laboratory Corporation of America Holdings
• 16.16. Lonza Group AG
• 16.17. Merck KGaA
• 16.18. Pace Analytical Services, LLC
• 16.19. Promega Corporation
• 16.20. QIAGEN N.V.
• 16.21. QPS Holdings LLC
• 16.22. Samsung Biologics Co., Ltd.
• 16.23. SGS SA
• 16.24. Syngene International Limited
• 16.25. Thermo Fisher Scientific Inc.
• 16.26. Toxikon Corporation
• 16.27. WuXi AppTec Co., Ltd.